Why Medicare Advantage isn’t as popular for first-year Medicare beneficiaries.
While enrollment in Medicare Advantage has grown rapidly over the past decade, the majority of Medicare beneficiaries choose to enroll in traditional Medicare during their first year on Medicare, according to the Kaiser Family Foundation (KFF).
A KFF Issue Brief found that older adults and younger beneficiaries with disabilities have said that they make this choice based on premiums and out-of-pocket costs, access to desired providers, the reputation of the company offering the plan, ads and other marketing materials, and the advice of brokers, family members, and friends.
Medicare Advantage offers one-stop shopping, with all Medicare benefits in one combined package, and enrollees may have lower out-of-pocket costs than those in traditional Medicare, with an out-of-pocket cap and coverage of some additional benefits, such as eyeglasses. Beneficiaries in traditional Medicare have open access to providers and fewer administrative hassles, such as prior authorization and referral requirements.
“We found that less than one-third (29%) of Medicare beneficiaries enrolled in Medicare Advantage plans during their first year on Medicare,” says Gretchen Jacobson, an associate director of the KFF’s Program on Medicare Policy. Most new beneficiaries (71%) were covered under traditional Medicare for their first year on Medicare.
“Enrollment rates among new Medicare beneficiaries were much higher in areas with high Medicare Advantage penetration rates and much lower in areas with low Medicare Advantage penetration rates,” Jacobson says. “In essence, new Medicare beneficiaries seem to be making care choices that are similar to other beneficiaries in their area.”
What States are Doing to Regulate Pharmacy Benefit Managers
March 26th 2024In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers found that state-level PBM reform focused on more transparent drug pricing, better patient access to prescription drugs, and more stringent auditing and reporting requirements.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
New approvals this week include a $4.25 million gene therapy, a drug that treats hypertension in a new way, a nonsteroidal drug for Duchenne, and an oral drug for aggressive leukemia. The agency has set an action date for resubmitted Lymphir in rare skin cancer, and Celltrion has launched Zymfentra, a subcutaneous form of infliximab.
Read More
How Health Insurers Can Create Remarkable Experiences in a Rapidly Changing Industry
March 22nd 2024The health industry is changing rapidly, and organizations that don’t adapt are going the way of the Model T. By offering new solutions and capabilities, successful organizations are supporting their customers with whole-person, full-journey care.
Read More